BetterLife Pharma Inc. is a life sciences company creating and clinically validating an evolving intellectual property portfolio of novel molecules and drug delivery mechanisms for clinical trials and commercialization.
At BetterLife we put comfort and accessibility at the centre of everything we do and believe how we treat a condition is as important as the treatment itself.
This is why we are committed to developing products that have a solid scientific and clinical foundation for commercialization of affordable and patient friendly medicine.
For example, TD-0148A is a second-generation Lysergic Acid Diethylamide (“LSD”) derivative molecule that mimics the projected therapeutic potential of LSD. Due to its non-regulated & non-scheduled status, it will be cheaper to develop than LSD. In addition, due to its non-hallucinogenic nature, which means patients can use it without the fear of unpredictable hallucinations, it is possible for patients to self-administer the treatment in the comfort of their own home without supervision by a trained therapist.
We are proud of our partners, which include Carleton University Department of Neuroscience, University of California San Diego, and more. Together we are advancing BetterLife’s vision, which is a future where individuals can live a full life without compromise.